Du är här

2015-09-11

Bavarian Nordic A/S: Bavarian Nordic issues Financial Calendar for 2016

COPENHAGEN, Denmark - September 11, 2015
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced its financial
calendar for the year 2016.

---------------------------------------------------------------------------------------------------
| March 15, 2016 2015 Annual Report |
| April 20, 2016 Annual General Meeting |
| May 13, 2016 First quarterly report (Q1) for the three-month period ended 31 March 2016 |
| August 17, 2016 Half-year report (Q2) for the six-month period ended 30 June 2016 |
| November 9, 2016 Third quarterly report (Q3) for the nine-month period ended 30 September 2016 |
---------------------------------------------------------------------------------------------------
Pursuant to Article 12 of the Articles of Association, shareholders who wish
to submit a request for proposals for consideration at the Annual General
Meeting must lodge this with the Company no later than Thursday, March 10,
2016.

Moreover, it should be noted that Bavarian Nordic in a period of two weeks
before planned publication of quarterly reports (silent periods), will not
comment specifically on developments or financial issues and expectations.

Contacts

Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43

Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271

About Bavarian Nordic

Bavarian Nordic is a biopharmaceutical company focused on the development and
manufacturing of cancer immunotherapies and vaccines for infectious diseases.
Through a long-standing collaboration with the U.S. Government, Bavarian
Nordic has developed a portfolio of biological countermeasures, including the
non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for
emergency use by the U.S. and other governments. The vaccine is approved in
the EU (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its
partner Janssen are pioneering the development of an Ebola vaccine, which has
been fast-tracked by authorities in response to the current situation in West
Africa. Additionally, in collaboration with the National Cancer Institute,
Bavarian Nordic has developed a portfolio of active cancer immunotherapies
based on its versatile pox-virus based technologies, including PROSTVAC®,
which is currently in Phase 3 clinical development for the treatment of
advanced prostate cancer. The company has partnered with Bristol-Myers Squibb
for the potential commercialization of PROSTVAC. For more information
visitwww.bavarian-nordic.comor follow us on Twitter@bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. We
undertake no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances after the date made,
except as required by law.

201525en
http://hugin.info/100065/R/1951067/709471.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire

HUG#1951067

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.